eprintid: 10142386 rev_number: 12 eprint_status: archive userid: 608 dir: disk0/10/14/23/86 datestamp: 2022-01-25 11:53:27 lastmod: 2022-01-25 11:53:27 status_changed: 2022-01-25 11:53:27 type: article metadata_visibility: show creators_name: Sabanathan, S creators_name: Abdel-Mannan, O creators_name: Mankad, K creators_name: Siddiqui, A creators_name: Das, K creators_name: Carr, L creators_name: Eltze, C creators_name: Eyre, M creators_name: Gadian, J creators_name: Hemingway, C creators_name: Kaliakatsos, M creators_name: Kneen, R creators_name: Krishnakumar, D creators_name: Lynch, B creators_name: Parida, A creators_name: Rossor, T creators_name: Taylor, M creators_name: Wassmer, E creators_name: Wright, S creators_name: Lim, M creators_name: Hacohen, Y title: Clinical features, investigations, and outcomes of pediatric limbic encephalitis: A multicenter study ispublished: inpress divisions: UCL divisions: B02 divisions: C07 divisions: D07 divisions: F87 note: © 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/). abstract: OBJECTIVES: To describe the clinical presentation, investigations, management, and disease course in pediatric autoimmune limbic encephalitis (LE). METHODS: In this retrospective observational study, from the UK Childhood Neuroinflammatory Disease network, we identified children from six tertiary centers with LE <18 years old between 2008 and 2021. Clinical and paraclinical data were retrieved from medical records. RESULTS: Twenty-five children fulfilling LE criteria were identified, with median age of 11 years (IQR 8, 14) and median follow-up of 24 months (IQR 18, 48). All children presented with seizures; 15/25 (60%) were admitted to intensive care. Neuroimaging demonstrated asymmetric mesial temporal changes in 8/25 (32%), and extra-limbic changes with claustrum involvement in 9/25 (38%). None were positive for LGI1/CASPR2 antibodies (Abs), 2/25 were positive for serum anti-NMDAR Abs, and 2/15 positive for anti-Hu Abs; one died from relapsing neuroblastoma. Two children had serum and CSF anti-GAD antibodies. Initial immune therapy included steroids in 23/25 (92%), intravenous immunoglobulin (IVIg) in 14/25 (56%), and plasma exchange in 7/25 (28%). The commonest second-line treatment was rituximab in 15/25 (60%). Median duration of hospital admission was 21 days (IQR 11, 30). At last follow-up, 13/25 (52%) had refractory seizures and 16/25 (64%) had memory impairment. Six children (24%) had modified Rankin Scale (mRS) scores ≥3. There was no significant difference in mRS, or long-term cognitive and epilepsy outcomes in those who received rituximab versus those who did not. INTERPRETATION: A diagnosis of autoimmune LE was associated with significant morbidity and adverse outcomes in this pediatric cohort. date: 2022-01-11 date_type: published official_url: https://doi.org/10.1002/acn3.51494 oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1915671 doi: 10.1002/acn3.51494 language_elements: English lyricists_name: Abdel-Mannan, Omar lyricists_name: Hacohen, Yael lyricists_id: OABDE15 lyricists_id: YHACO24 actors_name: Flynn, Bernadette actors_id: BFFLY94 actors_role: owner full_text_status: public publication: Annals of Clinical and Translational Neurology event_location: United States citation: Sabanathan, S; Abdel-Mannan, O; Mankad, K; Siddiqui, A; Das, K; Carr, L; Eltze, C; ... Hacohen, Y; + view all <#> Sabanathan, S; Abdel-Mannan, O; Mankad, K; Siddiqui, A; Das, K; Carr, L; Eltze, C; Eyre, M; Gadian, J; Hemingway, C; Kaliakatsos, M; Kneen, R; Krishnakumar, D; Lynch, B; Parida, A; Rossor, T; Taylor, M; Wassmer, E; Wright, S; Lim, M; Hacohen, Y; - view fewer <#> (2022) Clinical features, investigations, and outcomes of pediatric limbic encephalitis: A multicenter study. Annals of Clinical and Translational Neurology 10.1002/acn3.51494 <https://doi.org/10.1002/acn3.51494>. (In press). Green open access document_url: https://discovery-pp.ucl.ac.uk/id/eprint/10142386/1/Ann%20Clin%20Transl%20Neurol%20-%202022%20-%20Sabanathan%20-%20Clinical%20features%20%20investigations%20%20and%20outcomes%20of%20pediatric%20limbic.pdf